Eli Lilly and Co. (NYSE:LLY) – Equities researchers at Leerink Swann reduced their FY2016 EPS estimates for Eli Lilly and in a research note issued on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will earn $3.48 per share for the year, down from their previous forecast of $3.57. Leerink Swann currently has a “Outperform” rating and a $92.00 target price on the stock. Leerink Swann also issued estimates for Eli Lilly and’s Q4 2016 earnings at $0.92 EPS, FY2017 earnings at $3.99 EPS and FY2018 earnings at $4.17 EPS.

Several other research analysts have also recently issued reports on the company. Goldman Sachs Group Inc. raised Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $89.00 to $95.00 in a research report on Tuesday, September 27th. Morgan Stanley set a $73.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a research report on Thursday, November 24th. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Jefferies Group reaffirmed a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research report on Wednesday, September 14th. Finally, Argus upped their price objective on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Eli Lilly and currently has an average rating of “Buy” and an average price target of $108.34.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Co. (LLY) to Post FY2016 Earnings of $3.48 Per Share, Leerink Swann Forecasts” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/29/eli-lilly-and-co-lly-to-post-fy2016-earnings-of-3-48-per-share-leerink-swann-forecasts.html.

Eli Lilly and (NYSE:LLY) opened at 67.20 on Monday. The company has a market capitalization of $71.08 billion, a P/E ratio of 29.23 and a beta of 0.28. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $88.16. The firm has a 50-day moving average price of $76.26 and a 200 day moving average price of $77.88.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the previous year, the company earned $0.89 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year.

A number of institutional investors have recently added to or reduced their stakes in LLY. Iowa State Bank acquired a new stake in Eli Lilly and during the second quarter valued at about $104,000. Tradewinds Capital Management LLC boosted its stake in Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares during the period. PineBridge Investments L.P. boosted its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the period. Integrated Wealth Management boosted its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the period. Finally, Financial Architects Inc boosted its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the period. 73.93% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Co. (LLY) to Post FY2016 Earnings of $3.48 Per Share, Leerink Swann Forecasts” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/29/eli-lilly-and-co-lly-to-post-fy2016-earnings-of-3-48-per-share-leerink-swann-forecasts.html.

In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.20% of the company’s stock.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.